Enhancing Clinical Competence in CIAS: A Case-Based Approach With AI Integration
Released On
December 18, 2024
Expires On
December 18, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Psychiatry, Neurology, Primary Care
Topics
Mental Health, Schizophrenia
Provider Statement
This activity is provided by Integrity CE, LLC.
Disclosure of Commercial Support
This activity is supported by an educational grant from Bristol Myers Squibb.
Credit Available
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Program Overview
Before the voices, before the hallucinations — easily identifiable symptoms of the psychosis that is common in schizophrenia — people with this psychiatric disorder often show signs of having difficulty with learning, problem solving, remembering details, or expressing thoughts. These are often unrecognized early harbingers of schizophrenia. Referred to as cognitive impairment associated with schizophrenia (CIAS), difficulty learning and problem solving is now believed to be a prodromal phase that can appear many years before the psychotic symptoms that are the hallmark of schizophrenia. Sadly, there are no treatments to address CIAS as all currently available antipsychotics show efficacy only for the “positive” signs of schizophrenia (eg, delusions, paranoia).
Join schizophrenia expert Dr. Daniel C. Javitt as he discusses this unmet need, along with ways that artificial intelligence may or may not assist in lessening the burdens associated with the management of schizophrenia.
Target Audience
This activity addresses the needs of psychiatrists, psychiatry mental health therapists (eg, psychologists, social workers, case managers), nurse practitioners, physician assistants, pharmacists, primary care providers and other clinicians involved in the management of patients with CIAS.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Describe the immediate and long-term effects of CIAS
- Identify neurotransmitters and brain regions involved in the pathophysiology of CIAS that cause its manifestations to differ from symptoms in the negative domain
- Plan to incorporate an emerging therapeutic agent for CIAS into therapeutic options for appropriately selected patients with schizophrenia based on safety, efficacy, and mechanism of action
Faculty
Daniel C. Javitt, MD, PhD
Professor and Director, Division of Experimental Therapeutics
Department of Psychiatry
Columbia University Irving Medical Center
New York, New York
Director, Schizophrenia Research
Nathan Kline Institute for Psychiatric Research
Orangeburg, New York
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts Of Interest
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Daniel C. Javitt, MD, PhD
Consultant: SK Life Science
Data, Safety, Monitoring Board Member: Biogen
Internal Speaker: Boehringer Ingelheim
Major Shareholder: NRx Pharmaceuticals
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. During the period of December 18, 2024 through December 18, 2025 participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].